Short-course eflornithine in Gambian trypanosomiasis: A multicentre randomized controlled trial

Bulletin of the World Health Organization

Volumn 78, Issue 11, 2000, Pages 1284-1295

  Pépin, Jacques ^a   Khonde, Nzambi ^b   Maiso, Faustine ^c   Doua, Félix ^d   Jaffar, Shabbar ^e   Ngampo, Stéphane ^f   Mpia, Bokelo ^b   Mbulamberi, Dawson ^c   Kuzoe, Felix ^g  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b National Sleeping Sickness Control Programme ^*  (Congo)

^c Natl Sleeping Sickness Contr Prog   (Uganda)

^d Projet de Recherches Cliniques sur la Trypanosomiase   (Côte d’Ivoire)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f Programme National de Lutte Contre la Trypanosomiase   (Congo)

^g WORLD BANK   (United States)

Author keywords

Eflorithine, adverse effects; Eflornithine, administration and dosage; Randomized controlled trials; Trypanocidal agents; Trypanosoma brucei gambiense; Trypanosomiasis, African, drug therapy

Indexed keywords

EFLORNITHINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLEEDING; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CULTURE; CLINICAL TRIAL; CONGO; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; COTE D'IVOIRE; DIARRHEA; DRUG EFFICACY; FEMALE; HEARING LOSS; HUMAN; INFECTION; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PLEOCYTOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCHOOL CHILD; STUPOR; TREATMENT FAILURE; TRYPANOSOMA GAMBIENSE; TRYPANOSOMIASIS; UGANDA; VOMITING;

ADOLESCENT; ADULT; AFRICA, CENTRAL; AGED; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; EFLORNITHINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS, AFRICAN;

EID: 0033750528     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. In the heart of darkness: Sleeping sickness in Zaire
2. Human African trypanosomiasis: An emerging public health crisis
3. The treatment of human African trypanosomiasis
4. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness
5. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness
6. Effect of ornithine decarboxylase inhibitors dl-α-difluoromethylornithine and α-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models
7. Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness
8. CNS toxicity and CSF pharmacokinetics of intraventricular DFMO and MGBG in beagle dogs
9. Epidemiological evidence for immunity following Trypanosoma brucei gambiense sleeping sickness
10. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to dl-α-difluoromethylornithine
11. A seven days course of eflornithine for relapsing Trypanosoma brucei gambiense sleeping sickness
12. Necessity of antibody response in the treatment of African trypanosomiasis with alpha-difluoromethylornithine
13. Gamblensetrypanosomiasis: Frequency of, and risk factors for, failure of melarsoprol therapy
14. Risk factors for treatment failure after melarsoprol for T.b. gambiense trypanosomiasis in Uganda
15. Eflornithine (Ornidyl) treatment of Trypanosoma brucei gambiense sleeping sickness; report of 711 patients treated up to March 1991
16. Novel approaches to the chemotherapy of trypanosomiasis
17. Future prospects for the chemotherapy of human trypanosomiasis. 2. Combination therapy and African trypanosomiasis